Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Summary

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis is a clinical trial^[1].

Key Facts

• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis is in the country of United States^[2].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's instance of is recorded as clinical trial^[3].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's start time is recorded as +2022-08-31T00:00:00Z^[4].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's end time is recorded as +2028-08-01T00:00:00Z^[5].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's main subject is recorded as sclerosis^[6].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's main subject is recorded as multiple sclerosis^[7].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's number of participants is recorded as {'unit': '1', 'amount': '+175'}^[8].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's title is recorded as Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS05)^[9].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's ClinicalTrials.gov ID is recorded as NCT05285891^[11].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+55'}^[12].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's research intervention is recorded as ocrelizumab^[13].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's research intervention is recorded as immunologic factor^[14].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's clinical trial phase is recorded as phase IV clinical trial^[15].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's research site is recorded as University of Michigan^[16].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's research site is recorded as University of Pennsylvania^[17].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's research subject recruitment status is recorded as not yet recruiting^[18].
• Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis's study type is recorded as interventional study^[19].